RNAC: Cartesian Therapeutics, Inc. Common Stock Company Profile & Statistics

Cartesian Therapeutics, Inc. Common Stock Profile

About

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Info & Links

CEO

Carsten Brunn

Headquarters

7495 New Horizon Way
Frederick, MD 21703, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

107

Employees

Cartesian Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

212.31M

Enterprise Value

51.98M

Enterprise Value/EBITDA(ttm)

-0.61

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

4.40

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

Profit Margin(ttm)

-653.35%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-3612.46%

Return on Assets(ttm)

-6.36%

Income Statement

Revenue(ttm)

1.03M

Revenue Per Share(ttm)

0.04

Gross Profit(ttm)

1.03M

EBITDA(ttm)³

-85.49M

Net Income Available to Common(ttm)

-34.68M

Diluted EPS(ttm)

Share Statistics

Beta (5Y Monthly)

0.39

52-Week Change

-61.45%

S&P 500 52-Week Change

19.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

26.00M

Dividend Yield

0.00%

Float⁴

10.32M

% Held by Insiders

60.30%

% Held by Institutions

86.95%

Balance Sheet

Total Cash(mrq)

160.32M

Total Cash Per Share(mrq)

6.17

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.33%

Quick Ratio(mrq)

13.33%

Book Value Per Share(mrq)

-0.10

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.54

Free Cash Flow(ytd)

-44.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

RNAC

Cartesian Therapeutics, Inc. Common Stock